IGF2BP3 (IMP3) expression in angiosarcoma, epithelioid hemangioendothelioma, and benign vascular lesions

Abstract

Background: Insulin-like growth factor-2 messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is an oncofetal protein that is expressed in various cancer types, and its expression is often associated with poor prognosis. IGF2BP3 expression has not been fully settled in vascular lesions. Methods: We evaluated the expression of IGF2BP3 in malignant (angiosarcoma and epithelioid hemangioendothelioma [EHE]) and benign (hemangioma, granulation tissue cappilaries, and pyogenic granuloma) vascular lesions using immunohistochemistry. IGF2BP3 expression was scored as negative (0% of endothelial/neoplastic cells), equivocal (1-25%), or positive (> 26%). Results: Eight of 30 (26.7%) cases of angiosarcoma and two of five (40%) cases of epithelioid hemangioendothelioma were positive for IGF2BP3. In contrast, hemangiomas (10 cases) and granulation tissue capillaries (12 cases) were all negative for IGF2BP3, and some cases of pyogenic granuloma (six of 14 cases) was scored as equivocal. In angiosarcoma, IGF2BP3 expression was independent of age, gender, location, morphological pattern, prognosis, presence of metastatic foci, and PD-L1 expression. Conclusions: IGF2BP3 is a useful marker to distinguish between malignant and benign vascular lesions.

Immunohistochemistry of the oncofetal protein IMP3 is helpful in the diagnosis of intravascular large B‐cell lymphoma using skin biopsy

“…In the present study, the majority of lymphoma cells expressed IMP3 in all 25 SBs from patients with IVL. It has been reported that IMP3 is partially expressed in non‐neoplastic inflammatory cells and benign skin tumors 6,8 . However, none of the 27 SBs from patients without IVL harbored intravascular IMP3‐positive B‐cells.…”

“…It has been reported that IMP3 is partially expressed in non-neoplastic inflammatory cells and benign skin tumors. 6,8 However, none of the 27 SBs from patients without IVL harbored intravascular IMP3-positive B-cells.…”

Epigenetic Regulation of Immune and Inflammatory Responses in Rheumatoid Arthritis

“…In the screening for m6A-related proteins, only IGF2BP3 was found to be related to RA; therefore, we theorized that it was a crucial factor influencing RA-related m6a methylation. IGF2BP3, one of the readers of m6A methylation, has been shown to play a regulatory role in many diseases including cancer ( 40 – 42 ) and cardiovascular diseases ( 43 , 44 ); however, its role in RA is unknown. In this study, we found that IGF2BP3 is mainly involved in the regulation of inflammation-related pathways, including the MAPK signaling pathway.…”

IMP3 promotes re‐endothelialization after arterial injury via increasing stability of VEGF mRNAhv

“…Finally, to further determine whether or not a direct interaction between IMP3 and VEGF mRNA IMP3, also known as insulin-like growth factor 2 (IGF2) mRNAbinding protein 3 (IGF2BP3), is a member of the insulin-like growth factor 2 mRNA-binding proteins family. [28][29][30] IMPs play its role in post-translational RNA processing, such as transcript localization, translation and stabilization [31][32][33] ; additionally, IMPs family were recently identified as a family of m6A readers. 8,34 However, previous research mainly focussed on the biological functions of IMPs in tumours and embryogenesis.…”